Abstract
5523Background: In GOG 213, a phase III randomized trial designed to determine the impact of secondary cytoreduction and/or incorporation of anti-angiogenesis therapy on overall survival (OS) in re...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have